Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -2.46.EBIT: As of FY2026 Q1, the actual value is USD -87.34 M.<h3>Financial Position</h3>As of March 31, 2026, Eikon Therapeutics, Inc. reported $596.0 million in cash, cash equivalents, and marketable securities, an increase from $336.0 million as of December 31, 2025. Total assets stood at $850.8 million as of March 31, 2026, up from $594.7 million as of December 31, 2025. Total liabilities decreased to $300.2 million from $312.3 million over the same period. Total stockholders’ equity significantly improved to $550.7 million as of March 31, 2026, from a deficit of - $879.0 million as of December 31, 2025.<h3>Operating Expenses</h3>Research and Development (R&amp;D) expenses for the first quarter of 2026 were $70.0 million, marking a 24% increase (or $13.5 million) from $56.6 million in the first quarter of 2025, primarily due to accelerated clinical trial activity and a $5.0 million milestone payment for EIK1003’s advancement. General and Administrative (G&amp;A) expenses rose to $17.3 million in the first quarter of 2026, a 17% increase (or $2.5 million) from $14.8 million in the prior-year period, mainly driven by higher depreciation and professional fees. Total operating expenses for the first quarter of 2026 were $87.3 million, compared to $71.4 million in the first quarter of 2025.<h3>Net Loss</h3>Loss from operations for the first quarter of 2026 was - $87.3 million, compared to - $71.4 million for the first quarter of 2025. Net loss and comprehensive loss for the first quarter of 2026 was - $83.0 million, compared to - $68.2 million for the first quarter of 2025. Net loss attributable to common stockholders for the first quarter of 2026 was - $83.0 million, compared to - $74.5 million for the prior-year period. Basic and diluted net loss per share attributable to common stockholders was - $2.46 for the first quarter of 2026, a notable improvement from - $26.91 for the first quarter of 2025.<h3>Other Financial Items</h3>Net interest income was $4.4 million for the first quarter of 2026, up from $3.2 million for the first quarter of 2025. Other income (expense), net, was - $1 thousand for the first quarter of 2026, compared to - $20 thousand for the first quarter of 2025. The impact of preferred stock extinguishments and modifications was zero for the first quarter of 2026, an improvement from - $6.3 million for the first quarter of 2025.<h3>Operational Highlights</h3>Eikon Therapeutics, Inc. continued to advance its oncology pipeline, focusing on EIK1001, EIK1003, and EIK1005, with six abstracts accepted for the ASCO annual meeting detailing new safety, tolerability, and efficacy data. The company also published a manuscript in the Journal of Medicinal Chemistry on single molecule tracking (SMT) to advance discovery programs. The EIK1001-005 study is fully enrolled, and the EIK1003 Phase 2 randomized dose optimization trial is currently dosing patients, with its Phase 1⁄2 Trial Initial Dose Escalation fully enrolled. Eikon Therapeutics, Inc. successfully advanced the WRN program (EIK1005) from a tool compound to a clinical candidate in less than 18 months, and EIK1006 was designated a clinical candidate in November 2025, with preclinical studies progressing ahead of schedule.<h3>Outlook</h3>Eikon Therapeutics, Inc. anticipates its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2027. The company expects meaningful progress across all development efforts in 2026 and beyond, focusing on disciplined execution to achieve additional clinical milestones. Upcoming events include multiple data readouts for EIK1001, EIK1003, and EIK1005 at the 2026 ASCO meeting, alongside the initiation of new clinical trial phases and IND submissions for EIK1004 and EIK1006 by the end of 2026.

Eikon Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0